Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

187 results about "Virus antigen" patented technology

A virus antigen is a toxin or other substance given off by a virus which causes an immune response in its host.

Method for inducing an immune response

PCT designated stage expiredWO2024228149A2Dispersion deliveryViral antigen ingredientsReplication competent virusVirus antigen
The present invention relates to methods for inducing an immune response in a subject, the method comprising administering orally to the subject an immunogenic composition comprising non-replicating virus antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinant virus capsid protein capable of forming a virus-like particle. This allows to simply induce an immune response in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.
Owner:BOEHRINGER INGELHEIM VETMEDICA GMBH

Porcine epidemic diarrhea virus antigen fusion protein, coding gene and porcine epidemic diarrhea vaccine prepared from porcine epidemic diarrhea virus antigen fusion protein

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI

Porcine Seneca Valley virus neutralizing liquid-phase blocking ELISA kit and its application

The present invention discloses a porcine Seneca virus neutralization liquid phase blocking ELISA kit, which comprises an effective amount of porcine Seneca virus antigen, an effective amount of porcine Seneca virus single domain antibody 1, an effective amount of porcine Seneca virus single domain antibody 2, and a matching detection reagent. The porcine Seneca virus antigen is porcine Seneca virus particles purified by sucrose density gradient centrifugation, and the particle size of the purified porcine Seneca virus particles is 20 to 30 nm. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 1 is shown in SEQ ID NO.1. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 2 is shown in SEQ ID NO.2. The kit of the present invention has the advantages of high efficiency, simplicity, sensitivity, stability, etc., has a good correlation with the traditional diagnostic method virus neutralization experiment, and is suitable for a wide range of applications.
Owner:浙江洪晟生物科技股份有限公司 +1

Respiratory syncytial virus antigenic polypeptides, nucleic acids and vaccines

The invention provides a respiratory syncytial virus antigenic polypeptide, nucleic acid and a vaccine. Compared with the respiratory syncytial virus wild type Pre-F protein, the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment of the respiratory syncytial virus antigenic polypeptide has the following changes: the 104th to 144th regions of the Pre-F protein are replaced with GS linker; two groups of disulfide bonds are introduced into S155C, S290C, A149C and Y458C; the S190F and the V207L are used for realizing cavity filling; and P102A, L373R, I379V, M447V, P102A, L373R, the C terminal of the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment thereof comprises a cytoplasm tail region fragment, and the cytoplasm tail region fragment is a fragment derived from 3-10 continuous amino acid residues of a PreF protein cytoplasm tail region. According to the present invention, the pre-F immunogenicity and / or stability can be improved, and the protein expression level can be easily improved.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Respiratory syncytial virus antigenic polypeptide, vaccine, and use

PCT designated stage expiredWO2025031486A1SsRNA viruses negative-senseViral antigen ingredientsF proteinRespiratory syncytial virus antigen
Provided are a respiratory syncytial virus antigenic polypeptide, a vaccine, and a use. First, a respiratory syncytial virus antigenic polypeptide or an immunogenic fragment thereof is provided. Compared with the amino acid sequence of a respiratory syncytial virus wild-type pre-F protein, the amino acid sequence of the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment thereof has one or more mutation sites of amino acid residues at the following positions: positions 174-176, positions 181-184, positions 210-213, and positions 160-161. The improvement of pre-F immunogenicity can be achieved and / or the protein expression level can be improved.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Infectious bovine rhinotracheitis virus antigen detection kit

The utility model relates to the field of antigen detection kits, and discloses an infectious bovine rhinotracheitis virus antigen detection kit which comprises a box body, a roller is rotatably connected to the bottom side in the box body, a clamping groove is formed in the upper side of the roller, a clamping pin is connected to the clamping groove in a clamping mode, and a placing table is fixedly connected to the upper side of the clamping pin. A plurality of swab placing grooves, an extraction tube placing groove and a detection card placing groove are respectively formed in the upper side of the placing table, the plurality of swab placing grooves, the extraction tube placing groove and the detection card placing groove are distributed in a circumferential array, and sampling swabs are arranged on the inner sides of the plurality of swab placing grooves; according to the utility model, a plurality of groups of sampling swabs, sample extraction tubes and antigen detection cards which are distributed in a circumferential array manner are placed on the placement table, so that when sampling personnel go to cattle for sampling one by one, the sampling personnel can rotate to detection materials such as the next group of antigen detection cards and the like only by pressing down the push rod and switching the angle of the placement table, and the operation is convenient and the use is simple.
Owner:INST OF ANIMAL HUSBANDRY & VETERINARY MEDICINE JIANGXI ACAD OF AGRI SCI

Preparation method of fusion protein of salmonella typhimurium flagellin and Seneca virus antigen

The invention belongs to the technical field of biology, and discloses a preparation method of fusion protein of salmonella typhimurium flagellin and Seneca virus antigen. Escherichia coli Rosetta (DE3) is selected as a host, a salmonella typhimurium flagellin gene and a Seneca virus antigen gene are fused and are cloned to a pET-28a (+) vector after codon optimization, the obtained fusion protein keeps the flagellin adjuvant activity, the solubility and the expression level of VP2 are improved, the yield can reach 40 mg / L, and the fusion protein can be used for preparing a recombinant vector. The expression and purification process cost is greatly reduced. The fusion protein provided by the invention can activate a TLR5 pathway and mouse macrophages, is simple in production process and low in cost, and has important significance on research and production of Seneca virus subunit vaccines.
Owner:LANZHOU UNIV

Preparation method of triple detection kit for influenza A, influenza B and new coronavirus antigens

The invention discloses a preparation method of a triple detection kit for influenza A, influenza B and new coronavirus antigens, and belongs to the field of respiratory virus in-vitro detection. In the antibody labeling stage, the antigen and the antibody can be more sufficiently combined in a manner of adding the linking arm, so that the antigen detection sensitivity can be improved. In the metal spraying stage, a novel coronavirus monoclonal antibody, an influenza A virus monoclonal antibody and an influenza B virus monoclonal antibody marked by latex microspheres are sequentially subjected to multi-layer metal spraying at the same position by a metal spraying instrument, the two antibodies are isolated by a trehalose solution, and metal spraying of three layers of antibodies isolated from each other is completed. And the cross reaction between different antibodies of the conjugate pad in the storage process is avoided, so that non-specific binding is avoided, and the storage stability is improved. The detection kit prepared by the method can specifically detect the novel coronavirus, the influenza A virus and the influenza B virus, and has the advantages of high sensitivity, good repeatability and the like.
Owner:BAODING ABIORES CHIP CO LTD +1

Bovine nodular skin disease virus chimeric antigen and application of bovine nodular skin disease virus chimeric antigen in ELISA (enzyme-linked immuno sorbent assay) detection kit

The invention relates to the technical field of immunodetection, and discloses a bovine nodular skin disease virus chimeric antigen and application thereof in an ELISA (enzyme-linked immuno sorbent assay) detection kit. According to the chimeric antigen, a gene of a dominant region of a bovine nodular skin disease virus antigen is selected to design a chimeric antigen gene, meanwhile, sequence optimization is performed, a chemical synthesis method is used for synthesizing a coding gene of the chimeric antigen of the bovine nodular skin disease virus, and then the chimeric antigen is obtained in a prokaryotic expression mode. An ELISA antibody detection kit developed on the basis of the chimeric antigen has extremely high sensitivity and specificity, can rapidly and specifically detect bovine nodular skin disease virus antibodies in serum, is suitable for monitoring and checking the nodular skin diseases of cattle in large-scale breeding, and has relatively high practical value.
Owner:CHINA AGRI UNIV

Influenza virus detection test strip based on cellulose nanospheres and preparation method thereof

PendingCN119125555Alow detection limitStrong specificityMaterial analysisCelluloseInfluenza B virus antigen
The invention relates to an influenza virus detection test strip based on cellulose nanospheres and a preparation method thereof, and belongs to the technical field of immunodetection. Cellulose nanospheres are used for replacing a traditional colloidal gold material and used for preparing the immunochromatography test strip, a sample pad, a combination pad, a coating film and a water absorption pad are sequentially formed on a bottom plate from a sample adding end, an influenza A virus detection line and an influenza B virus detection line are arranged on the coating film, and the water absorption pad is arranged on the bottom plate. The test strip provided by the invention is applied to detection of influenza A and B virus antigens, the detection limit is as low as 0.05 ng / mL and 0.25 ng / mL, the detection test strip has lower detection limit and better specificity due to the use of the cellulose nanospheres, the preparation process is simplified, the stability of the test strip is also improved, and the test strip has wide application prospects.
Owner:SHAOXING BEYOND MEDICAL TECH CO LTD

RSV vaccine composition, method and use thereof

An immunogenic composition comprising a recombinant peptide and a protein, wherein the recombinant peptide and the protein comprise a respiratory syncytial virus (RSV) viral antigen and an immunogen such as an RSV F protein peptide. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen is linked with the C-terminal part of collagen by means of in-frame fusion to form a disulfide bond-linked trimer fusion protein. The immunogenic composition can be used for producing an immune response, for example for treating or preventing RSV infection. The immunogenic composition can be used in a vaccine composition, for example as part of a prophylactic and / or therapeutic vaccine. Further provided are a method for producing the recombinant peptide and protein, prevention, treatment and / or diagnosis methods and related kits.
Owner:SICHUAN CLOVER BIOPHARM INC

Encapsulin fusion protein for expressing foot and mouth disease virus epitope and application of Encapsulin fusion protein in preparation of subunit vaccine

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

A kit for detecting porcine epidemic diarrhea and its preparation method

The present invention relates to a kit for detecting porcine epidemic diarrhea and a preparation method thereof, belonging to the technical field of virus detection, and specifically comprising the following steps: after extracting the antigen, treating it with a virus purification agent containing polyethylene glycol, nuclease and concanavalin, and then obtaining a virus antigen suspension with a composite dissociation solution. The suspension is coated on a microporous reaction plate to form a solid-phase antigen. Subsequently, the porcine epidemic diarrhea virus solid-phase antigen, enzyme marker, sample diluent, Tris buffer, color developer and stop solution are aseptically stored to prepare a kit for detecting porcine epidemic diarrhea. The present invention provides a novel kit and a preparation method thereof, which can not only effectively purify porcine epidemic diarrhea virus, but also significantly reduce the risk of protein precipitation, while overcoming nucleic acid interference and improving purification efficiency.
Owner:TAIZHOU LEILING BIOTECH CO LTD

A T cell receptor, a preparation method thereof and uses thereof

The present invention relates to the field of biomedicine, and particularly to a T cell receptor and its preparation method and use. The T cell receptor EBV-TCR of the present invention comprises a variable region of the TCRα chain and a variable region of the TCRβ chain; the variable region of the TCRα chain contains peptide segments CDRα1, CDRα2, and CDRα3; the variable region of the TCRβ chain contains peptide segments CDRβ1, CDRβ2, and CDRβ3; the amino acid sequence of CDRα3 is as shown in SEQ ID NO.7, and the amino acid sequence of CDRβ3 is as shown in SEQ ID NO.3. The TCR of the present invention has high specificity, and binding to T cells can significantly activate cytokine release, providing a solid theoretical and experimental basis for the development of TCR-T therapy targeting Epstein-Barr virus antigens.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Immunogenic composition useful for self-administration by pigs

The present invention relates to immunogenic compositions comprising (i) an antigen composition which comprises or consists of a virus antigen and (ii) a gel composition comprising a flavoring agent, wherein such immunogenic composition can be placed into the housing environment of livestock, in particular of pigs. Thereby the self-administration of the immunogenic composition by the pigs is enabled, which allows to simply induce an immune response in the animals, by a minimum workload for personnel and less stress for the pigs.
Owner:BOEHRINGER INGELHEIM VETMEDICA GMBH

Methods and kits for virus detection

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and / or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and / or tissue damage response biomarkers; and / or extracellular vesicles in response to a viral infection.
Owner:MESO SCALE TECH LLC

Respiratory syncytial virus antigenic polypeptide, nucleic acid, vaccine and application thereof

PendingCN119490569ASsRNA viruses negative-senseVirus peptidesRespiratory syncytial virus antigenVirus antigen
The invention provides a respiratory syncytial virus antigenic polypeptide, nucleic acid, a vaccine and application thereof. The invention firstly provides a respiratory syncytial virus antigenic polypeptide or an immunogenic fragment thereof, and the respiratory syncytial virus antigenic polypeptide has at least 26th-470th or full-length amino acid sequence as shown in SEQ ID NO: 1, or a derivative amino acid sequence which is formed by replacing, deleting or adding one or more amino acids on the basis of the amino acid sequences and has the same function. According to the invention, the pre-F immunogenicity can be improved and / or the protein expression level can be improved.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Influenza virus antigen detection kit

The utility model relates to the field of detection kits, and discloses an influenza virus antigen detection kit which comprises a kit box, two partition plates are arranged on the inner walls of the two sides of the kit box, a plurality of test cards are arranged in the kit box, first detection grooves are formed in the front ends of the upper surfaces of the test cards, and second detection grooves are formed in the front ends of the upper surfaces of the test cards. A first detection strip is arranged on the inner bottom surface of the first detection groove, a second detection groove is formed in the rear end of the upper surface of the test card, and a second detection strip is arranged on the inner bottom surface of the second detection groove. Compared with the existing detection kit, the detection kit provided by the utility model has the advantages that through the arrangement of the test card and the arrangement of the two detection grooves in the test card, the detection strips for detecting different viruses are respectively placed in the detection grooves, so that the purpose of detecting two viruses by one test card can be achieved; and meanwhile, the material loss can be effectively reduced, so that the production cost of the test card is further reduced.
Owner:BEIJING CCIC ANTAI DIAGNOSTIC TECH CO LTD

Inactivation method for improving recovery rate of enterovirus antigen

The invention relates to the technical field of virus antigens, and particularly discloses an inactivation method for improving the recovery rate of enterovirus antigens. The method disclosed by the invention specifically comprises the following steps: adding a protective agent with the final concentration of 50-250 [mu] g / ml into purified enterovirus liquid; after fully and uniformly mixing, stirring and incubating the mixed solution; the protective agent is prepared by mixing TritionX-100, arginine and lysine; the incubation temperature is 25-40 DEG C, and the incubation time is 4-12 hours; then adding a formaldehyde solution until the final concentration is 180-220 mu g / ml, and inactivating for 68-76 hours under the condition that the temperature is 35-39 DEG C, so as to obtain an inactivated vaccine; and finally, washing and filtering the inactivated solution to remove TritionX-100 and formaldehyde in the sample. According to the technical scheme, the recovery rate of the antigen in the inactivation solution is greatly improved, and the residual quantity of TritionX-100 and formaldehyde is small.
Owner:LIAONING CHENGDA BIOTECH

Linear covalent closed DNA vaccine as well as preparation method and application thereof

The invention relates to a linear covalent closed DNA vaccine, which comprises a plasmid vector containing an IHNV virus antigen expression unit, the sequence of the antigen expression unit is shown as SEQ ID NO.1, and the DNA structural form is a linear terminal covalent closed form. The invention also relates to a preparation method and application of the linear covalent closed DNA vaccine. Compared with a traditional DNA vaccine, the linear covalent closed DNA vaccine has no redundant bacterium source nucleic acid sequence, and has good safety and effectiveness for preventing and treating infectious hematopoietic necrosis of rainbow trout.
Owner:EAST CHINA UNIV OF SCI & TECH +1

Self-assembled protein cage nanoparticle antigen epitope insertion site and application thereof in vaccine preparation

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Preparation method and use of respiratory syncytial virus antigen

A protein for preventing respiratory syncytial virus infection and a use thereof. On the basis of RSV F protein sequences, specific I and IV epitope sequences of post-F and common III epitope partial sequences of pre-F and post-F are removed to obtain new F antigen sequences; and the two new F antigen sequences are then connected in series to form a new F antigen dimer, and the new F antigen dimer is maintained in pre-F conformation in vivo and in vitro, thereby stimulating an organism to generate an antibody which is specific to a pre-F epitope and has high neutralizing activity. The dimer antigen has the advantages of stimulating an organism to generate more neutralizing antibodies and having a high yield.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Chimeric EB virus antigen and application thereof

The invention discloses an EB (Epstein-Barr) virus antigen with chimeric design and application thereof. The EB virus chimeric antigen provided by the invention is reasonably designed on the basis of structural biology, gL, gH and gp42 proteins of the EB virus are connected through a linker, and the chimeric designed antigen stably presents antigen epitopes of the three proteins at the same time, so that the production amplification process and quality control can be simplified while the vaccine immunogenicity is improved. The EB virus chimeric antigen can be used independently or in combination with other antigens, has high immunogenicity when being used as a vaccine or a vaccine component, can induce an immunized animal to generate a high-level neutralizing antibody, can be used for preparing a vaccine for preventing or treating EB virus infection, and can also be used as a reagent for detecting EB virus.
Owner:SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD

A neutralizing monoclonal antibody against Epstein-Barr virus gB antigen and its application

The present invention discloses a neutralizing monoclonal antibody against Epstein-Barr virus gB antigen and its application. The antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises heavy chain CDR-H1 shown in SEQ ID NO:15; heavy chain CDR-H2 shown in SEQ ID NO:16; and heavy chain CDR-H3 shown in SEQ ID NO:17. The light chain variable region comprises light chain CDR-L1 shown in SEQ ID NO:18; light chain CDR-L2 shown in SEQ ID NO:19; and light chain CDR-L3 shown in SEQ ID NO:20. The antibody in the present invention can specifically recognize Epstein-Barr virus gB antigen and has a good neutralizing effect, so that various expression vectors and transformants can be developed based on the antibody, and thus can be effectively used for the detection, prevention and treatment of Epstein-Barr virus.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Multicistronic Vaccine and Methods for Producing and Using the Same

The present disclosure provides multicistronic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and / or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.
Owner:OCUGEN INC

Colloid detection kit and detection card for nasopharynx cancer diagnosis and screening and application of colloidal detection kit and detection card

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.
Owner:SHENZHEN GENEBIOHEALTH

An mRNA based on the CP protein gene of fish neuronecrosis virus, a vaccine, and its preparation method and application

The present invention relates to the field of biomedicine technology, and specifically discloses an mRNA based on the CP protein gene of fish nervous necrosis virus, a vaccine, and a preparation method and application thereof. The present invention provides an mRNA of fish nervous necrosis virus, the nucleotide sequence of which is shown in SEQ ID NO: 1, and the structure includes a 5' untranslated region, a signal peptide sequence, an NNV virus antigen coding region, a 3' untranslated region and polyA. The mRNA vaccine contains the ORF sequence of the capsid protein CP gene that is resistant to NNV virus infection. The results of animal safety tests on the fish nervous necrosis virus mRNA vaccine prepared by the present invention show that the vaccine is safe and effective, and is convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral nervous necrosis in marine cultured fish.
Owner:SHANGHAI OCEAN UNIV

A method, kit and application of rapid viral antigen detection signal amplification

The present invention belongs to the technical field of analysis and detection, and specifically relates to a method for rapid detection of viral antigens, a test kit and its application. In order to solve the problem of low detection sensitivity commonly found in antigen detection kits, the present invention is a four-test card in a flat circle, which surrounds a shared unique detection hole and is, in turn, a sample card, a first series antibody card, a second series antibody card and a third series antibody card. The sample test card includes a sample pad, a conjugation pad, an NC membrane and a water-absorbing pad. The layout of the first, second and third series antibody cards is similar, including a wash pad and a conjugation pad, and behind the test card on the NC membrane is the quality control line of each card.
Owner:SHANXI UNIV

Application of rhizoma kaempferiae extract in preparation of medicine for resisting avian infectious bronchitis virus

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.
Owner:JIANGSU AGRI ANIMAL HUSBANDRY VOCATIONAL COLLEGE

Oral vaccine against carp spring viremia virus, its preparation method and application

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.
Owner:HENAN NORMAL UNIV